Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%

Serious adverse events · Patients with active Crohn's disease

Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.63 [0.41, 0.98]
1 study · 342 participants
Moderate

Serious adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 2.42 [0.1, 56.46]
1 study · 45 participants
Very low

Serious adverse events · Patients with active Crohn's disease

Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.12 [0.77, 1.62]
1 study · 324 participants
Moderate